Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Stallergenes's Oralair - sublingual allergen extract gets approval from FDA

    Recently, U.S. Food and Drug Administration approved Oralair, first sublingual allergen extract approved in the United States, to treat allergic rhinitis with or without conjunctivitis that is induced by certain grass pollens in age group of 10 to 65 years. Oralair contains a mixture of freeze-dried extracts from the pollens of five grasses, including Kentucky Blue Grass, Orchard, Perennial Rye, Sweet Vernal and Timothy.

  • Study shows Party drug- KETAMINE can treat severe depression

    The scientists,  from Oxford Health NHS, confirmed that some patients with severe depression who have not responded to other treatments, can be treated with ketamine which has a rapid antidepressant effect. Ketamine is a licensed medical drug and is very widely used as an anaesthetic and in pain relief. It is also used as a recreational drug or drug of abuse, and is to be reclassified as a Class B banned substance.

  • New drug approved for treating psoriatic arthritis by FDA

    The U.S. Food and Drug Administration approved Otezla (apremilast), manufactured for Celgene Corporation, Summit, N.J.,  to treat adults with active psoriatic arthritis (PsA), which is a form of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with PsA. Joint pain, stiffness and swelling are the main signs and symptoms of PsA.

  • HIV-positive men at higher risk for Heart Disease

    Formation of plaques is more frequent in coronary arteries of HIV positive men than HIV negative men, according to a new study by National Institutes of Health grantees. The research describes that HIV-infected men are at higher risk for a heart attack than their HIV-uninfected which is published in Annals of Internal Medicine.

  • Manufacturers invited to present their proposal in office of DCGI for approval of the safety and efficacy of FDCs

    Fixed Dose Combinations (FDCs) manufacturers are invited to present their proposal for approval of the safety and efficacy of permitted for manufacture for sale in the country without due approval from office of Drug Controller General of India (DCGI).

  • India reaches remarkable milestone as 'Polio Free Nation' certified by WHO

    On thursday, 27th march 2014, the World Health Organisation (WHO) presented official certification to India for its ‘Polio Free’ status. India is among other countries in its South East Asian region which have been certified as being free of the wild polio virus. Ghulam Nabi Azad, health minister of India, received the official certificate from WHO.

  • FDA approves first implantable hearing device

    The U.S. Food and Drug Administration approved the first implantable device for people 18 and older with severe or profound sensorineural hearing loss of high-frequency sounds in both ears, but who can still hear low-frequency sounds with or without a hearing aid. The Nucleus Hybrid L24 Cochlear Implant System may help those with this specific kind of hearing loss who do not benefit from conventional hearing aids.

  • Scientists identified genetic diversity of K.Pneumoniae (drug-resistant bacteria)

    New findings, by group of scientists, will facilitate the development of new clinical strategies design to prevent or treat infections caused by multidrug-resistant Klebsiella Pneumoniae. Scientists from National Institutes of Health (NIH) and their colleagues have tracked the evolution of the Carbapenem-resistant bacterium K.pneumoniae sequence type 258 (ST258), an important agent of hospital-acquired infections by using genome sequencing.

    [adsense:336x280:8701650588]

  • Health Ministry notified on implementation of Schedule H1 drugs in D&C rules | No more OTC selling of antibiotics

    The Drugs and Cosmetics Rules, 1945 (D&C rules) were amended vide Drugs and Cosmetics (Fourth Amendment) Rules, 2013 published under Gazette notification G.S.R. 588(E) dated 30.08.2013 regarding the inclusion of Schedule H1 under the D&C rules containing certain antibiotics, anti-TB drugs and habit forming drugs. The notification states that these rules will come into force after six months of their publication in the official Gazette i.e. from 1st March, 2014

  • New discovery can delay Alzheimer's development

    Researchers from Michigan University have found out cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and looks like major cause of Alzeimer's Disease (AD). this mechanism helps decode amyloid plaque formation in the brains of Alzheimer's patients—plaques that kills cells and contributes to memory loss and other Alzheimer's symptoms.
    The researchers discovered the molecular process behind Golgi fragmentation, and also developed two techniques to 'rescue' the Golgi structure.

Subscribe to Pharma News